Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Galera Therapeutics stock

Learn how to easily invest in Galera Therapeutics stock.

Galera Therapeutics Inc is a biotechnology business based in the US. Galera Therapeutics shares (GRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Galera Therapeutics employs 30 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Galera Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Galera Therapeutics stock price (NASDAQ: GRTX)

Use our graph to track the performance of GRTX stocks over time.

Galera Therapeutics shares at a glance

Information last updated 2022-09-26.
Latest market close$1.73
52-week range$1.12 - $8.50
50-day moving average $1.40
200-day moving average $2.03
Wall St. target price$11.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.95

Buy Galera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Galera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galera Therapeutics price performance over time

Historical closes compared with the close of $1.73 from 2022-09-29

1 week (2022-09-23) 12.34%
1 month (2022-09-01) 34.11%
3 months (2022-07-01) 34.11%
6 months (2022-03-31) -27.31%
1 year (2021-10-01) -78.67%
2 years (2020-10-01) -82.36%
3 years (2019-09-27) N/A
5 years (2017-09-27) N/A

Galera Therapeutics financials

Gross profit TTM $0
Return on assets TTM -42.47%
Return on equity TTM -1063.11%
Profit margin 0%
Book value N/A
Market capitalisation $41.6 million

TTM: trailing 12 months

Galera Therapeutics share dividends

We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.

Galera Therapeutics share price volatility

Over the last 12 months, Galera Therapeutics's shares have ranged in value from as little as $1.12 up to $8.5. A popular way to gauge a stock's volatility is its "beta".

GRTX.US volatility(beta: 2.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galera Therapeutics's is 2.0294. This would suggest that Galera Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Galera Therapeutics overview

Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. .

Frequently asked questions

What percentage of Galera Therapeutics is owned by insiders or institutions?
Currently 5.518% of Galera Therapeutics shares are held by insiders and 43.066% by institutions.
How many people work for Galera Therapeutics?
Latest data suggests 30 work at Galera Therapeutics.
When does the fiscal year end for Galera Therapeutics?
Galera Therapeutics's fiscal year ends in December.
Where is Galera Therapeutics based?
Galera Therapeutics's address is: 2 West Liberty Boulevard, Malvern, PA, United States, 19355
What is Galera Therapeutics's ISIN number?
Galera Therapeutics's international securities identification number is: US36338D1081
What is Galera Therapeutics's CUSIP number?
Galera Therapeutics's Committee on Uniform Securities Identification Procedures number is: 36338D108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site